. Author manuscript; available in PMC: 2017 Jan 1.

Published in final edited form as: Expert Opin Ther Pat. 2016;26(3):323–345. doi: 10.1517/13543776.2016.1154045

Table 3.

Studies involving the use of monoclonal antibodies targeting FXI and/or FXIa.

Monoclonal antibody	Binding site	Positive results in animal models	References
076D-M007 076D-M028-H17	The former binds to the catalytic domain and the latter to the apple domain	1) FeCl₃-induced arterial occlusion (rabbits) 2) Ear bleeding assay (rabbits) 3) Collagen-initiated arteriovenous shunt thrombosis (baboons) 4) Template skin bleeding test (baboon)	113
XI-5108	Binds the catalytic domain	1) Balloon-induced injured neointima of the iliac artery (rabbits) 2) Endothelial denudation and vessel ligation-induced thrombosis in jugular vein (rabbits)	114 & 115
O1A6 (aXIMab)	Binds to A3 domain	1) Collagen-initiated arteriovenous shunt thrombosis (baboons) 2) Template skin bleeding test (baboon)	117 & 118
14E11	Binds to A2 domain	1) FeCl₃-induced arterial occlusion (mice) 2) TF-induced pulmonary embolism (mice) 3) Acute ischemic stroke (mice) 4) Collagen-initiated arteriovenous shunt thrombosis (baboons) 5) Polymicrobial sepsis (mice) 6) Lethal listeriosis (mice) 7) Tail bleeding assay (mice)	119-122
αFXI-175 αFXI-203	The former binds to A4 domain and the latter to A2 domain	1) FeCl₃-induced thrombosis in vena cava inferior (mice) 2) Tail bleeding assay (mice)	123